QIAGEN N.V. (QGEN) Form 6-K — Nov 5, 2026
QIAGEN reported Q3 2026 net sales of $548 million, up 3% (also +3% CER, beating its 1-2% CER outlook), with adjusted diluted EPS of $0.65 versus an outlook of at least $0.62 CER. GAAP diluted EPS fell to $0.51 from $0.60 a year ago on higher restructuring and tax charges. The bigger story is the pending acquisition by EQT Private Equity: Crown NL Bidco B.V. will make an all-cash offer of €46.50 per share for all QIAGEN shares, with closing expected in mid-2027 and unanimous board support.
Key figures
- Eps
- 0.51
- Revenue
- 548000000
- Net Income
- 106000000
- Revenue Yoy
- 3%
- Total Assets
- 5942470000
- Cash Position
- 805000000
- Leverage ratio
- 1.0x net debt to adjusted EBITDA
- Expected closing
- mid-2027
- Free cash flow 9m
- 319000000
- Adjusted diluted eps
- 0.65
- Operating cash flow 9m
- 447000000
- Takeover price per share
- EUR 46.50
- Adjusted operating income
- 167000000
- Adjusted operating margin
- 30.4%
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.